Should the standard dimethyl sulfoxide concentration be reduced? Results of a <scp>E</scp>uropean <scp>G</scp>roup for <scp>B</scp>lood and <scp>M</scp>arrow <scp>T</scp>ransplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide
Curly Morris(Belfast Health and Social Care Trust), Liesbeth C. de Wreede(Radboud University Nijmegen), Tapani Ruutu(Helsinki University Hospital), Marcus Hentrich(Red Cross Hospital), Patrizia Chiusolo(Agostino Gemelli University Polyclinic), Thomas Pabst(University Hospital of Bern), Francesco Onida(Peter MacCallum Cancer Centre), Ebbe Dickmeiss(Rigshospitalet), Giovanni Martinelli(University of Bologna), Jane F. Apperley(Hammersmith Hospital), Marijke Scholten(Radboud University Nijmegen), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Anja van Biezen(European Society for Blood and Marrow Transplantation), Marek Trněný(Charles University), Stig Lenhoff(Lund University), Théo de Witte(Radboud University Nijmegen), Ronald Brand(Universität Hamburg), Michael Quinn(University of Ulster), Nicolaus Kröger(Universität Hamburg), Gustaaf W. van Imhoff
Cited by 94
Related Papers
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k